Pharmacology and pharmacokinetics of LEX 032, a bioengineered serpin: the first of a potential new class of drugs.
Sands
H
H
Sparta Pharmaceuticals, Inc., Horsham, Pennsylvania 19044, USA.
Hook
J B
JB
D000818:Animals; D002448:Cell Adhesion / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D009504:Neutrophils / Q000187:drug effects* / Q000502:physiology*; D011994:Recombinant Proteins / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D015427:Reperfusion Injury / Q000188:drug therapy / Q000473:pathology; D015842:Serine Proteinase Inhibitors / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D015843:Serpins / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D014947:Wounds and Injuries / Q000188:drug therapy / Q000473:pathology
C095800:LEX 032; D011994:Recombinant Proteins; D015842:Serine Proteinase Inhibitors; D015843:Serpins